This was supported not least by the fact that patients with mutations in beta amyloid precursor protein (β-APP) (which is a precursor for Aβ), including patients with Down’s syndrome (β-APP is located on chromosome 21), developed AD, whereas patients with tau mutations developed a spectrum of different neurodegenerative disorders, often with parkinsonian symptoms. This evidence concerns the gene MAPT and Alzheimer disease.